Hjem › Kastringsresistent prostatakræft › New York
Kastringsresistent prostatakræft kliniske forsøg i New York
8 studier for Kastringsresistent prostatakræft søger deltagere på steder i New York.
Byer i New York
Officiel studietekst (engelsk)
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola
- NYU Langone Health Laura and Isaac Perlmutter Cancer Center, New York
- Montefiore Medical Center, The Bronx
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07225946A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- NYU Langone Hospitals, Brooklyn
- NYU Langone Hospital Long Island, Mineola
- NYU Langone Health Laura and Isaac Perlmutter Cancer Center, New York
- og 1 flere
RekruttererFase 3
Alder 18 og opefter · Mænd · Opdateret 25. sep. 2026 · NCT07164443A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- Memorial Sloan Kettering Cancer Center ( Site 0006), New York
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT06863272Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- Northwell Health R.J. Zuckerberg Cancer Hospital, Lake Success
- NYU Langone Health Long Island, Mineola
- NYU Langone Health, New York
- og 3 flere
RekruttererFase 1
Alder 18 til 100 · Mænd · Opdateret 13. aug. 2026 · NCT05519449A Study of MGC026 in Participants With Advanced Solid Tumors
- START-New York Long Island, Lake Success
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 11. aug. 2026 · NCT06242470A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
- Memorial Sloan Kettering Cancer Center, New York
RekruttererFase 1
Alder 18 og opefter · Mænd · Opdateret 10. aug. 2026 · NCT0606784164Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
- Weill Cornell Medicine at New York-Presbyterian, New York
RekruttererFase 1/2
Alder 18 og opefter · Mænd · Opdateret 6. maj 2026 · NCT04868604Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
- Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York
RekruttererFase 1
Alder 18 og opefter · Mænd · Opdateret 21. nov. 2025 · NCT05743621Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.